Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

ViewPoints: Covid-19 Impact On Global Telemedicine Market

The concept of telemedicine has evolved in recent years. As people are demanding easier ways to avail of medical treatment and diagnosis, there have been several advances in telemedicine. Telemedicine is a method that involves providing clinical services through a distance. Through telemedicine, the user doesn’t necessarily have to be present at the hospital or […]Read More

PharmaShots Webinar: Deal And Venture Trends Through The First Half

On September 2, 2020, Octavus Consulting and DealForma will present their most recent data and trends on dealmaking across biopharma, device, diagnostics, and digital health. Healthcare and life sciences deal and venture activity through August 2020 has not slowed down despite the challenges thrown at business leaders globally. We will review recent trends covering the […]Read More

Cadila to Launch its Cadalimab (biosimilar, adalimumab) in India

Shots: Cadalimab will be available in 40mg/0.8ml as a pre-filled syringe and is targeted for the reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Psoriasis Additionally, Cadila has launched 3 more biosimilar products Bevaro, Ritucad, and NuPTH in the last 2 months Adalimumab is a mAb and […]Read More

Insights+: The US FDA New Drug Approvals in July 2020

The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally, […]Read More

Formycon with its Partner BIOEQ Plans to Initiate P-III MAGELLAN-AMD

Shots: BIOEQ will sponsor the P-III study which will assess the FYB203 vs Eylea in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy, safety and immunogenicity. Additionally, the design of the study is developed in collaboration with the USFDA, EMA, PMDA The second program in ophthalmology will aim to strengthen and expand […]Read More

Evotec and Centogene Expand their Collaboration to Target Gaucher Disease

Shots: The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform, including iPSC lines The collaboration follows […]Read More

BioSymetrics Signs an Agreement with Janssen and Sema4 to Utilize

Shots: The companies will use BioSymetrics Contingent-AI engine to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course and identify markers for clinical phenotype and severity of the disease The focus of the collaboration to predict the onset and severity of COVID-19 among different populations using machine learning […]Read More